The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Open accessAbstract
Overall survival analysis combining LUX-Lung 3 and LUX-Lung 6.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While OS analysis of the two studies, as well as both studies combined, indicated no significant OS improvement with afatinib versus chemotherapy (LUX-Lung 3/6 combined: 25.8 vs 24.5 months; HR, 0.91 (95% CI, 0.75–1.11), P = 0.37)”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [66]
In the citing paper
“a pre-specified subgroup analysis demonstrated that afatinib prolonged OS versus chemotherapy in patients with Del19-positive tumors, in both LUX-Lung 3 (33.3 vs 21.1 months; HR, 0.54 (95% CI, 0.36–0.79), P = 0.0015) and LUX-Lung 6 (31.4 vs 18.4 months; HR, 0.64 (95% CI, 0.44–0.94), P = 0.023).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [66]
In the citing paper
“Clinical trials have demonstrated that afatinib performs better in terms of overall survival than chemotherapy for those with EGFR exon 19 deletion, and provides an overall longer period of effective treatment and good disease control compared to gefitinib, a first-generation EGFR inhibitor.120–123”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [123]
In the citing paper
“although a pooled analysis of two studies with afatinib demonstrated an OS improvement in those patients harbouring the exon 19 deletion.12”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [12]
In the citing paper
“The third-generation EGFR-TKIs include the WZ4002, CO-1686, AZD9291 and HM61713 inhibitors, which have demonstrated tumour responses in >50% of patients with the EGFR T790M mutation.8–12”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [12]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Self-citation
Research works printed but not linked: 2
- Wu, 2013, First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): Interim analyses from the Phase 3, open-label, ENSURE study, J Thorac Oncol, 8, S603
- Ding, 2013, Exon 19 deletions, smoking history and gender as additional predictive factors for treatment benefit with EGFR tyrosine kinase inhibitors in patients harbouring activating EGFR mutations: a meta-analysis of 1432 patients in six randomised trials, J Thorac Oncol, 8
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Self-citationNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
“0374), whereas this improvement was not observed in patients with EGFR L858R mutations [II, A] [115].”
BackgroundSelf-citationPlanchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“More specifically, there was no difference in OS in patients with EGFR exon 19 mutation, which is contrary to the earlier claim of benefit in this subgroup from the pooled analysis of LUX-Lung 3 and LUX-Lung 6 studies [183].”
ResultSelf-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Metadata
- Authors
- Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., Lu, S., Huang, Y., Geater, S. L., Lee, K. Y., Tsai, C.-M., Gorbunova, V., Hirsh, V., Bennouna, J., Orlov, S., Mok, T., Boyer, M., Su, W.-C., Lee, K. H., Kato, T., Massey, D., Shahidi, M., Zazulina, V., & Sequist, L. V.
- Affiliations
- National Taiwan University (TW)
- Guangdong General Hospital (CN)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Royal Marsden Hospital (GB)
- Wakayama Medical University (JP)
- Tongji University (CN)
- Central South University (CN)
- Queensland University of Technology (AU)
- Jiangsu Cancer Hospital (CN)
- Kunming Medical University (CN)
- Prince of Songkla University (TH)
- Chungbuk National University (KR)
- Taipei Veterans General Hospital (TW)
- McGill University (CA)
- Institut de Cancérologie de l'Ouest (FR)
- Chinese University of Hong Kong (HK)
- Royal Prince Alfred Hospital (AU)
- National Cheng Kung University Hospital (TW)
- Kanagawa Cardiovascular and Respiratory Center (JP)
- Boehringer Ingelheim (United Kingdom) (GB)
- Harvard University (US)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 16
- Issue
- 2
- Pages
- 141-151
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2132870547
- Semantic Scholar
- 04655861b33a1f173b0e155bfe3b23797853be74
- Cited by
- 1,574
- References
- 30
- Citations by year
- 2026: 33 · 2025: 67 · 2024: 72 · 2023: 107 · 2022: 129 · 2021: 159 · 2020: 148 · 2019: 165 · 2018: 165 · 2017: 201 · 2016: 201 · 2015: 125
- FWCI
- 182.17
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.qut.edu.au
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by-nc-nd)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- afatinib, EGFR tyrosine kinase inhibitors, gemcitabine-cisplatin chemotherapy, overall survival, EGFR exon 19 deletion, advanced non-small cell lung cancer
- MeSH terms
- Pemetrexed, Afatinib, Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Deoxycytidine, Female, Follow-Up Studies, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Quinazolines, Survival Rate, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71173-8
- The paper
- Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., Lu, S., Huang, Y., Geater, S. L., Lee, K. Y., Tsai, C.-M., Gorbunova, V., Hirsh, V., Bennouna, J., Orlov, S., . . . Sequist, L. V. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71173-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.